TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32451120

Group type: EXPERIMENTAL
Intervention: Efavirenz 400 mg once daily for CYP2B6 516 GG genotype
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Efavirenz 300 mg once daily for CYP2B6 516 GT genotype
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Efavirenz 100 mg once daily for CYP2B6 516 TT genotype
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Efavirenz 800 mg once daily for HIV/tuberculosis co-infected patients with CYP2B6 516 GG genotype
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Efavirenz 600 mg once daily for HIV/tuberculosis co-infected patients with CYP2B6 516 GT genotype
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Efavirenz 200 mg once daily for HIV/tuberculosis co-infected patients with CYP2B6 516 TT genotype
Number of subjects: 360

Group type: COMPARATOR
Intervention: Rifampicin co-administration
Number of subjects: 360
Study: 32451223

Group type: EXPERIMENTAL
Intervention: hs-cTnT
Number of subjects: 2437

Group type: EXPERIMENTAL
Intervention: hs-cTnI (Architect)
Number of subjects: 2437

Group type: EXPERIMENTAL
Intervention: hs-cTnI (Centaur)
Number of subjects: 2437
Study: 32451495

Group type: EXPERIMENTAL
Intervention: BL-8040 and pembrolizumab
Number of subjects: 37
Study: 32451615

Group type: EXPERIMENTAL
Intervention: Daclizumab beta 150 mg subcutaneously every 4 weeks for up to 6 years
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Daclizumab beta treatment
Number of subjects: 410
Study: 32451952

Group type: EXPERIMENTAL
Intervention: Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir plus Ribavirin for 12 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir plus Ribavirin
Number of subjects: 26
Study: 32452392

Group type: EXPERIMENTAL
Intervention: Semi-structured interviews with patients diagnosed with GTPS
Number of subjects: 10
Study: 32452462

Group type: EXPERIMENTAL
Intervention: Negative reactivity
Number of subjects: 291

Group type: COMPARATOR
Intervention: Positive reactivity
Number of subjects: 291
Study: 32452555

Group type: EXPERIMENTAL
Intervention: Promoting the administration of antenatal corticosteroids (ACS)
Number of subjects: 100705
Study: 32453126

Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) induction
Number of subjects: 13
Study: 32453169

Group type: EXPERIMENTAL
Intervention: Labour epidural analgesia
Number of subjects: 651

Group type: COMPARATOR
Intervention: No labour epidural analgesia
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: Predelivery anxiety and depression
Number of subjects: 651
Study: 32453209

Group type: EXPERIMENTAL
Intervention: Self-inserted pessary device
Number of subjects: 73
Study: 32453217

Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 0
Study: 32453485

Group type: EXPERIMENTAL
Intervention: Subcutaneous sarilumab
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Intravenous/subcutaneous tocilizumab
Number of subjects: 322
Study: 32453615

Group type: EXPERIMENTAL
Intervention: Mode of delivery
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Breastfeeding status
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Ethnicity
Number of subjects: 106
Study: 32453640

Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R therapy (3 cycles for low-risk, 6 cycles with CNS prophylaxis for high-risk)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R therapy
Number of subjects: 113
Study: 32453841

Group type: EXPERIMENTAL
Intervention: Anti-CD19 CAR T-cell therapy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Allogeneic hematopoietic stem cell transplant (allo-HSCT) after CAR T-cell therapy
Number of subjects: 110
Study: 32455108

Group type: EXPERIMENTAL
Intervention: Qigong
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham-Qigong
Number of subjects: 20
Study: 32455424

Group type: EXPERIMENTAL
Intervention: Higher anti-flagellin IgA
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Higher anti-LPS IgA
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Higher anti-LPS IgG
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Higher anti-flagellin IgG
Number of subjects: 548
Study: 32456619

Group type: EXPERIMENTAL
Intervention: Manual measurement using a mercury or aneroid device
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Ambulatory BP monitoring (ABPM)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Home BP monitoring (HBPM)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Automated office BP (AOBP)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: In-office BP readings
Number of subjects: 445
Study: 32456636

Group type: EXPERIMENTAL
Intervention: Ovaleap® (follitropin alfa)
Number of subjects: 463
Study: 32456684

Group type: EXPERIMENTAL
Intervention: Low-resolution pressure reactivity index (LPRx)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-resolution pressure reactivity index (PRx)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimal CPP based on LPRx
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimal CPP based on PRx
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deviations of actual CPP from optimal CPP values (both LPRx and PRx)
Number of subjects: 0
Study: 32457756

Group type: EXPERIMENTAL
Intervention: Aberrant lymphocyte phenotype with decreased naïve/memory T cell ratios and reduced numbers of switched memory B cells.
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Lower incidence of infectious events at adulthood.
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Increased risk of developing autoimmunity, malignancies, and infections.
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Compensated immune dysfunction in mid-life.
Number of subjects: 44
Study: 32457838

Group type: EXPERIMENTAL
Intervention: Anlotinib
Number of subjects: 0
Study: 32458022

Group type: EXPERIMENTAL
Intervention: Aortic valve neocuspidization using autologous pericardium (OZAKI procedure)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Echocardiographic follow-up
Number of subjects: 35
Study: 32458180

Group type: EXPERIMENTAL
Intervention: AFLU ablation in patients with SHD
Number of subjects: 3526

Group type: COMPARATOR
Intervention: AFLU ablation in patients without SHD
Number of subjects: 3526

Group type: EXPERIMENTAL
Intervention: Overall patient satisfaction with ablation therapy
Number of subjects: 3526
Study: 32458378

Group type: EXPERIMENTAL
Intervention: Vericiguat co-administered with various drugs (omeprazole, magnesium/aluminum hydroxide, ketoconazole, rifampicin, mefenamic acid, midazolam, warfarin, digoxin, sacubitril/valsartan, aspirin, sildenafil)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 0
Study: 32458996

Group type: EXPERIMENTAL
Intervention: Temsirolimus (25 mg weekly, intravenous infusion for 30-60 minutes)
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Temsirolimus
Number of subjects: 1001
Study: 32459419

Group type: EXPERIMENTAL
Intervention: Alcohol use before pregnancy (64.6%) vs during pregnancy (3.9% at visit 1, 5.6% at visit 2, 7.0% at visit 3, 6.1% at visit 4)
Number of subjects: 10038

Group type: EXPERIMENTAL
Intervention: Smoking rates before pregnancy (17.8%) vs during pregnancy (5.9% at visit 1, 5.3% at visit 2, 4.7% at visit 3, 3.9% at visit 4)
Number of subjects: 10038

Group type: EXPERIMENTAL
Intervention: Recreational drug use before pregnancy (33.8%) vs during pregnancy (1.1% at visit 2, 0.7% at visit 3, 0.4% at visit 4)
Number of subjects: 10038
Study: 32459430

Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids and magnesium sulfate
Number of subjects: 3093

Group type: COMPARATOR
Intervention: Antenatal corticosteroids alone
Number of subjects: 3093

Group type: COMPARATOR
Intervention: Magnesium sulfate alone
Number of subjects: 3093

Group type: COMPARATOR
Intervention: Neither therapy
Number of subjects: 3093
Study: 32459625

Group type: EXPERIMENTAL
Intervention: W@W-App + MetaWearC
Number of subjects: 20

Group type: COMPARATOR
Intervention: activPAL3M
Number of subjects: 20
Study: 32459639

Group type: EXPERIMENTAL
Intervention: Wearable blood pressure monitoring device (Health Gauge), daily self-monitoring of blood pressure and monthly evaluation for weight gain from 20 weeks of gestation until delivery
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard antenatal care with weight gain assessment every two months from 20 weeks of gestation until delivery
Number of subjects: 70
Study: 32459638

Group type: EXPERIMENTAL
Intervention: Prediction model for time to death within 60 minutes in potential cDCD patients
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Validation and updating of previous prediction models on time to death after WLST
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Assessment of timing and patient characteristics associated with prognostication and decision-making for end-of-life care
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Evaluation of the impact of timing of family approach on organ donation approval
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Assessment of variation in WLST processes on postmortem organ donor potential
Number of subjects: 400
Study: 32459655

Group type: EXPERIMENTAL
Intervention: Current patient monitoring equipment
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Wireless sensors
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Reduction in false-positive alarms
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Hospital standard operating procedures for alarm management
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: AI for early detection of complications
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Training on new technologies
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: AI-based intelligent alarm management
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Mobile phones for remote monitoring
Number of subjects: 86
Study: 32459723

Group type: EXPERIMENTAL
Intervention: Rhythmic auditory cueing during treadmill gait training
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Rhythmic auditory cueing during overground gait training
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Clinical tests of gait and balance
Number of subjects: 3
Study: 32459812

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32459957

Group type: EXPERIMENTAL
Intervention: MEDI3726 (an Anti-Prostate-Specific Membrane Antigen Pyrrolobenzodiazepine Antibody-Drug Conjugate)
Number of subjects: 0
Study: 32460196

Group type: EXPERIMENTAL
Intervention: LeanAN and RecAN patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 32460197

Group type: EXPERIMENTAL
Intervention: Crizotinib treatment
Number of subjects: 33
Study: 32460741

Group type: EXPERIMENTAL
Intervention: Posterior tibial nerve stimulation (PTNS)
Number of subjects: 0
Study: 32460798

Group type: EXPERIMENTAL
Intervention: INSPIRIS RESILIA aortic valve
Number of subjects: 400
Study: 32461211

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) derived coefficient of variation (CV) and glucose management indicator (GMI)
Number of subjects: 130

Group type: COMPARATOR
Intervention: A1C
Number of subjects: 130
Study: 32461262

Group type: EXPERIMENTAL
Intervention: 0.2 µg/day fluocinolone acetonide (FAc) implant
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (pre-FAc)
Number of subjects: 95
Study: 32461347

Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa 1200 mg every 2 weeks
Number of subjects: 30
Study: 32461698

Group type: EXPERIMENTAL
Intervention: Geospatial immune variability analysis
Number of subjects: 0
Study: 32461881

Group type: EXPERIMENTAL
Intervention: Team-based 'Get-a-Grip' lifestyle management programme
Number of subjects: 134
Study: 32462078

Group type: EXPERIMENTAL
Intervention: Rapidly switchable universal CAR-T cells (UniCAR-T) targeting CD123
Number of subjects: 0
Study: 32462131

Group type: EXPERIMENTAL
Intervention: Nicotine e-cigarettes
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Non-nicotine e-cigarettes
Number of subjects: 376

Group type: COMPARATOR
Intervention: No e-cigarettes (Counselling alone)
Number of subjects: 376
Study: 32462372

Group type: EXPERIMENTAL
Intervention: Preseason health examination (PHE) derived candidate prognostic factors
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Parsimonious model including age and frequency of previous IMIs
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Validated model after overfitting adjustment
Number of subjects: 152
Study: 32462665

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg
Number of subjects: 32
Study: 32462740

Group type: COMPARATOR
Intervention: Vitamin D3 (cholecalciferol) supplementation (20 participants)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Vitamin D3 100,000 IU/month (21 participants)
Number of subjects: 39
Study: 32462911

Group type: EXPERIMENTAL
Intervention: Machine learning-driven multibiomarker panel
Number of subjects: 0
Study: 32463014

Group type: EXPERIMENTAL
Intervention: Web-based positive emotion skills intervention (EMPOWER)
Number of subjects: 0
Study: 32463152

Group type: EXPERIMENTAL
Intervention: Cabozantinib (100 mg/day, later reduced to 60 mg/day)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 52
Study: 32463741

Group type: EXPERIMENTAL
Intervention: AZD4547
Number of subjects: 70
Study: 32463975

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus S-1 (GS) regimen
Number of subjects: 51
Study: 32463976

Group type: EXPERIMENTAL
Intervention: Circadian rhythm assessment
Number of subjects: 8
Study: 32464087

Group type: EXPERIMENTAL
Intervention: Belun Ring Platform
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Belun Ring total sleep time
Number of subjects: 50
Study: 32464183

Group type: EXPERIMENTAL
Intervention: Obesity clinic cohort
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Children with obesity and insulin resistance
Number of subjects: 543

Group type: COMPARATOR
Intervention: Population-based cohort
Number of subjects: 543
Study: 32464281

Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg/day for 1 year plus loperamide prophylaxis (days 1-28)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Budesonide + loperamide (days 1-28)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Colestipol + loperamide (days 1-28)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Colestipol + as-needed loperamide (days 1-28)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Neratinib dose escalation (DE)
Number of subjects: 501

Group type: COMPARATOR
Intervention: ExteNET study (historical control)
Number of subjects: 501
Study: 32464282

Group type: EXPERIMENTAL
Intervention: R-CODOX-M/R-IVAC chemotherapy (alternating cycles of CODOX-M and IVAC plus eight doses of rituximab)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: R-CODOX-M/R-IVAC chemotherapy
Number of subjects: 111
Study: 32464368

Group type: EXPERIMENTAL
Intervention: Salvage radiation therapy (sRT) with hormonal therapy
Number of subjects: 114

Group type: COMPARATOR
Intervention: Salvage radiation therapy (sRT) without hormonal therapy
Number of subjects: 114
Study: 32466779

Group type: EXPERIMENTAL
Intervention: First-line aromatase inhibitor (AI) treatment
Number of subjects: 103
Study: 32466781

Group type: EXPERIMENTAL
Intervention: Neoadjuvant rituximab
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 8
Study: 32467323

Group type: EXPERIMENTAL
Intervention: Alteplase 0.9 mg/kg intravenously
Number of subjects: 120
Study: 32467712

Group type: EXPERIMENTAL
Intervention: Moderate- to high intensity aerobic and resistance exercise for 20 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control group (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate- to high intensity exercise
Number of subjects: 0
Study: 32467765

Group type: EXPERIMENTAL
Intervention: Anti-IL5/IL5R therapy
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Anti-IgE therapy
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Biological therapy (general)
Number of subjects: 64
Study: 32468132

Group type: EXPERIMENTAL
Intervention: Can-Pain digital intervention
Number of subjects: 3
Study: 32468741

Group type: EXPERIMENTAL
Intervention: Vorico® Injection (test formulation)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Vfend® IV (reference formulation)
Number of subjects: 24
Study: 32469092

Group type: EXPERIMENTAL
Intervention: Dupilumab as add-on therapy to maximal standard of care
Number of subjects: 64
Study: 32469129

Group type: EXPERIMENTAL
Intervention: Wearable fitness device (Garmin Vivoactive HR) and exercise prescription (150 min of moderately to vigorous exercise per week)
Number of subjects: 30
Study: 32469185

Group type: EXPERIMENTAL
Intervention: Tepotinib (500 mg once daily)
Number of subjects: 152
Study: 32469386

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX (fluorouracil 400 mg/m2 bolus, 2400 mg/m2 over 46 hours; leucovorin 400 mg/m2; irinotecan 180 mg/m2; oxaliplatin 85 mg/m2) with trastuzumab for ERBB2-positive patients (6 mg/kg loading dose, then 4 mg/kg every 14 days)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Number of subjects: 67
Study: 32469399

Group type: EXPERIMENTAL
Intervention: Ceramide score (Q4 versus Q1)
Number of subjects: 2010

Group type: EXPERIMENTAL
Intervention: Sphingomyelins with fully saturated sphingoid-fatty acid pairs (Q4 versus Q1)
Number of subjects: 2010

Group type: EXPERIMENTAL
Intervention: Saturated-sphingomyelin score (Q4 versus Q1) after adjustment for traditional risk factors
Number of subjects: 2010
Study: 32469884

Group type: EXPERIMENTAL
Intervention: Fold-transition dynamics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uncorrelated dynamics
Number of subjects: 0
Study: 32470397

Group type: EXPERIMENTAL
Intervention: High-dimensional single-cell profiling (CyTOF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tissue-invading TAMs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Defining the specific immunological signature of brain tumors
Number of subjects: 0
Study: 32470848

Group type: EXPERIMENTAL
Intervention: Cabozantinib (60 mg orally once daily)
Number of subjects: 50
Study: 32471030

Group type: EXPERIMENTAL
Intervention: Nivolumab (12 patients), combination of nivolumab and ipilimumab (1 patient), pembrolizumab (remaining patients)
Number of subjects: 20
Study: 32471222

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 557

Group type: COMPARATOR
Intervention: Vitamin K Antagonists (VKAs)
Number of subjects: 557
Study: 32471422

Group type: EXPERIMENTAL
Intervention: RRS re-design including regular RRT meetings, RRT role badges, structured member-to-user hand-off process
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RRS re-design
Number of subjects: 0
Study: 32471438

Group type: EXPERIMENTAL
Intervention: Cervical vagus nerve stimulation (VNS)
Number of subjects: 32
Study: 32471493

Group type: EXPERIMENTAL
Intervention: SGRQ (Saint George's Respiratory Questionnaire)
Number of subjects: 1734

Group type: EXPERIMENTAL
Intervention: EQ VAS (EQ-5D Visual Analog Scale)
Number of subjects: 1734

Group type: EXPERIMENTAL
Intervention: FEV (Forced Expiratory Volume)
Number of subjects: 1734
Study: 32471909

Group type: EXPERIMENTAL
Intervention: Euglycemic condition (first scanning session)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hyperglycemic condition (second scanning session, 20 mmol/L [360 mg/dL])
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy control subjects (20 participants aged 14.40 ± 2.82 years)
Number of subjects: 20
Study: 32471990

Group type: EXPERIMENTAL
Intervention: Detection of gene fusions in patients with multiple myeloma
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Targeted fusion therapies
Number of subjects: 742
Study: 32472007

Group type: EXPERIMENTAL
Intervention: Standardised frankincense extract (SFE) taken daily for eight months
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Standardised frankincense extract (SFE)
Number of subjects: 28
Study: 32472137

Group type: EXPERIMENTAL
Intervention: Intrathecal ziconotide
Number of subjects: 93
Study: 32472191

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 1317

Group type: COMPARATOR
Intervention: Long-term glucose control
Number of subjects: 1317
Study: 32472278

Group type: EXPERIMENTAL
Intervention: Previous benign biopsy
Number of subjects: 532

Group type: COMPARATOR
Intervention: Biopsy-naïve men
Number of subjects: 532
Study: 32472319

Group type: EXPERIMENTAL
Intervention: CDX-014 administered intravenously at doses ranging from 0.15 to 2.0 mg/kg every 2 or 3 weeks until progression or unacceptable toxicity.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: CDX-014
Number of subjects: 16
Study: 32472503

Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 29
Study: 32473040

Group type: EXPERIMENTAL
Intervention: Double-guidewire technique (DWT) performed by trainees
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Double-guidewire technique (DWT)
Number of subjects: 60
Study: 32473283

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Exercise Testing (CPET) and Cardiac Magnetic Resonance imaging (CMR) in MDC carriers
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance imaging (CMR)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Subset analysis of LGE+ and LGE- subjects
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Cardiac and skeletal muscle impacts
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Functional assessment by treadmill
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Age, RecVE and serum CK
Number of subjects: 124
Study: 32473339

Group type: EXPERIMENTAL
Intervention: Dual fluoroscopy with live-image digital zooming
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard magnification
Number of subjects: 151
Study: 32473635

Group type: EXPERIMENTAL
Intervention: ApoCIII concentration measured in chylomicron-free serum (postprandial)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: ApoCIII concentration measured in chylomicron-free serum (fasting)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: ApoCIII concentration measured in native serum (postprandial)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: ApoCIII concentration measured in native serum (fasting)
Number of subjects: 195